XML 42 R20.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock Options | 12 Months Ended
--- | ---
Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock Options |
(1 2) | Stock Options
In August 2016, the Company’s board of directors adopted the 2016 Equity Incentive Plan (the 2016 Plan) for employees, directors, and consultants. As of December 31, 2017, 633,052 shares are available for issuance under the 2016 Plan, of which 429,750 shares were rolled from the 2013 Equity Incentive Plan (the 2013 Plan) into the 2016 Plan. In 2013, the Company’s board of directors adopted the 2013 Plan for employees, directors, and consultants. The common stock authorized under the 2013 Plan is 1,200,000 shares. Under the Plan, the administrator shall have authority to determine which service providers will receive awards, to grant awards and to set all terms and conditions of awards (including, but not limited to, vesting, exercise and forfeiture provisions). Vested options are canceled 90 days after termination of employment and become available for reissuance under the Plan. As of December 31, 2017 and December 31, 2016, no shares were available for issuance under the 2013 Plan. The service period for stock options granted to employees is generally 1 to 4 years. The grant-date fair value of each option award is estimated on the date of grant using the Black- Scholes-Merton option-pricing model. The weighted average assumptions for December 31, 2017, 2016 and 2015 grants are provided in the following table. The Company’s lack of historical share option exercise experience does not provide it a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options. Since the Company’s shares have only been publicly traded since August 12, 2016 and its shares were rarely traded privately, expected volatility is estimated based on the average historical volatility of similar entities with publicly traded shares. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve at the date of grant.
|  | As of December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Valuation assumptions: |  |  |  |  |  |  |  |  |  |  |  |
Expected dividend yield |  |  | 0 | % |  |  | 0 | % |  |  | 0 | %
Expected volatility |  |  | 39.37 | % |  |  | 41.82 | % |  |  | 56.74 | %
Expected term (years) |  |  | 6.06 |  |  |  | 6.07 |  |  |  | 5.42 |
Risk-free interest rate |  |  | 1.9 | % |  |  | 1.6 | % |  |  | 1.7 | %
Stock option activity during the periods indicated is as follows:
|  | Number of shares |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual term |
Balance at December 31, 2014 |  |  | 504,550 |  |  | $ | 2.60 |  |  |  | 5.8 |
Granted |  |  | 512,402 |  |  |  | 2.00 |  |  |  | 9.2 |
Exercised |  |  | (24,260 | ) |  |  | 3.19 |  |  |  | — |
Expired/Forfeited |  |  | (236,000 | ) |  |  | 2.77 |  |  |  | — |
Balance at December 31, 2015 |  |  | 756,692 |  |  | $ | 2.10 |  |  |  | 7.6 |
Granted |  |  | 359,319 |  |  |  | 2.60 |  |  |  | 9.4 |
Exercised |  |  | (58,155 | ) |  |  | 2.36 |  |  |  | 3.5 |
Expired/Forfeited |  |  | (17,469 | ) |  |  | 2.13 |  |  |  | 2.6 |
Balance at December 31, 2016 |  |  | 1,040,387 |  |  | $ | 2.25 |  |  |  | 7.8 |
Granted |  |  | 471,144 |  |  |  | 14.72 |  |  |  | 9.1 |
Exercised |  |  | (284,455 | ) |  |  | 2.07 |  |  |  | 5.2 |
Expired/Forfeited |  |  | (23,449 | ) |  |  | 8.22 |  |  |  | — |
Balance at December 31, 2017 |  |  | 1,203,627 |  |  | $ | 7.06 |  |  |  | 8.1 |
Vested and exercisable at December 31, 2017 |  |  | 523,566 |  |  | $ | 2.21 |  |  |  | 7.0 |
Vested and expected to vest at December 31, 2017 |  |  | 1,203,627 |  |  | $ | 7.06 |  |  |  | 8.1 |
The weighted average grant-date fair value of options granted during the years ended December 31, 2017, 2016 and 2015 was $6.02, $1.23 and $0.84, respectively. For fully vested stock options the aggregate intrinsic value was $3,596,624 and $7,770,086 as of December 31, 2017 and 2016, respectively. For stock options expected to vest the aggregate intrinsic value was $1,469,154 and $4,569,243 as of December 31, 2017 and 2016, respectively. At December 31, 2015, the aggregate intrinsic value for fully vested stock options and stock options expected to vest was immaterial. The total grant date fair value of shares vested during the years ended December 31, 2017, 2016 and 2015 was $322,804, $176,597 and $345,174, respectively. During the year ended December 31, 2016, a total of 57,475 shares of restricted common stock with a fair value of $2.00 per share were issued to the Company’s Chief Financial Officer and Chief Operating Officer of which 100% of the shares vested in the year ended December 31, 2017. At December 31, 2017, 2016 and 2015, there was $2,453,342, $522,818 and $214,304, respectively, of total unrecognized compensation cost related to unvested stock options and restricted stock granted under the plans. That cost is expected to be recognized over the next three years. The Company currently uses authorized and unissued shares to satisfy share award exercises.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration